The clinical course of CML involves not only the dysregulation of tyrosine kinase function, but also manifests as a deep dysfunctional immune response against tumor cells expressing the fusion gene BCR-ABL1. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.